Article Text

Download PDFPDF
Ebastine for the treatment of irritable bowel syndrome: old drug, new tricks?
  1. Alexander C Ford1,2
  1. 1 Leeds Gastroenterology Institute, St James's University Hospital, Leeds, UK
  2. 2 Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK
  1. Correspondence to Professor Alexander C Ford, Leeds Gastroenterology Institute, St James's University Hospital, Leeds, UK; alexford{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

There is increasing evidence that the pathophysiology of irritable bowel syndrome (IBS), once considered a functional gastrointestinal disorder and now reframed as a disorder of gut–brain interaction,1 has an organic basis. Some patients with IBS exhibit evidence of low-grade mucosal inflammation.2 One of the most well-replicated observations over the last 20 years has been reports of mast cell activation in IBS, with degranulation and a resulting increase in mucosal tryptase and histamine,3 as well as increased proximity of mast cells to visceral nerves, which correlate with abdominal pain severity and frequency. Colonic biopsy supernatants from patients with IBS are able to excite rat nociceptive visceral sensory nerves in vitro.4

The cause of mast cell activation in this group of patients is unknown. However, evidence suggests this could relate to a break in oral tolerance to a dietary antigen, following either an acute enteric infection or a psychological stressor. In a mouse model infected with Citrobacter rodentium and exposed to a dietary antigen during the infection, an adaptive immune response to the same dietary antigen occurred during subsequent exposure.5 This was IgE-mediated, was gut-specific and led to diarrhoea, altered gastrointestinal transit, and visceral hypersensitivity, all the hallmarks of IBS. In the same study, injection of …

View Full Text


  • Contributors ACF wrote and approved the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles